Pseudomonas aeruginosa reporting
Pseudomonas antibiogram software for Pseudomonas aeruginosa susceptibility by unit and source
The ICU asks whether piperacillin-tazobactam still covers its Pseudomonas, and the hospital-wide line cannot answer. Build the unit and source table from the lab export in an afternoon.
Try the builder on the sample data, or drop in your own CSV. It is parsed in your browser and never uploaded.
Short answer
A Pseudomonas antibiogram reports, for first Pseudomonas aeruginosa isolates per patient, the percent susceptible to the antipseudomonal agents you actually use (piperacillin-tazobactam, cefepime, ceftazidime, meropenem, ciprofloxacin, tobramycin and the newer agents) by unit, specimen source and year, with the isolate count beside every cell. Antimicrobe builds it from a lab CSV with no interface, applies the breakpoint version you choose. The cumulative table runs on the Lab plan from $249 a month, and unit cuts with quarterly trends are on the Stewardship plan at $749 a month.
Why Pseudomonas needs its own cut
Pseudomonas aeruginosa is the organism where a hospital-wide percentage misleads most. It concentrates in ICUs, in ventilated patients, in burn and cystic fibrosis care and in long-stay units, and the same drug can look reliable across the house while it fails in the place you most need it. Published unit-level studies find single-unit Pseudomonas susceptibility differing from the hospital-wide figure by 15 points or more, sometimes higher and sometimes lower, so a bedside choice built on the house line can be wrong in either direction for the sickest patients.
There is also a counting problem. Patients with chronic Pseudomonas colonization are cultured again and again, and every repeat pulls the percentage toward their strain. CLSI M39 asks for the first isolate per patient per period for exactly this reason. A Pseudomonas report that does not say which rule it used cannot be compared from one year to the next.
- Percent susceptible for P. aeruginosa by unit, specimen source and year, from the same dataset
- First isolate per patient per period, with the rule printed on the report
- Antipseudomonal beta-lactams, carbapenems, fluoroquinolones and aminoglycosides in one table
- Ceftolozane-tazobactam, ceftazidime-avibactam and other newer agents when your lab tests them
- A flag on every cell under 30 isolates, with the raw count shown instead of a percentage
Breakpoint changes that move Pseudomonas numbers
Few organisms have had as many breakpoint revisions in recent years. CLSI lowered the P. aeruginosa carbapenem breakpoints in 2012, revised piperacillin-tazobactam for P. aeruginosa in its 2022 M100 edition, and reworked the aminoglycosides in 2023, removing the gentamicin breakpoint for P. aeruginosa and lowering tobramycin. Each change can move a percentage by several points with no change in the bacteria. If your lab updated its instrument rules midway through a year, the annual Pseudomonas line mixes two definitions.
Antimicrobe records which breakpoint version produced each table and can re-run a year of MIC data under the current CLSI or EUCAST version, so the committee sees whether a drop in piperacillin-tazobactam susceptibility is resistance or a rule change. The same approach is described on the breakpoints page linked below.
| Lab export field | Pseudomonas report output |
|---|---|
| Organism name | P. aeruginosa rows identified, other Pseudomonas species reported separately |
| Specimen source, location, collection date | Susceptibility by unit, respiratory, blood and urine source, quarter and year |
| Drug, MIC or zone, S, I, R result | Percent susceptible per drug, re-runnable under a newer breakpoint version |
| Patient ID | One isolate per patient per analysis period |
A worked example from an ICU
Take a 220 bed hospital with 260 P. aeruginosa results in a year. After the first isolate rule, 171 patients remain. Hospital-wide, 152 of 171 are piperacillin-tazobactam susceptible, 88.9 percent. Filter to the medical and surgical ICUs combined and 41 isolates remain, of which 31 are susceptible, 75.6 percent. Filter again to respiratory specimens from the ICU and the count drops to 26, under the 30 isolate threshold, so the report shows the raw count and suggests pooling two years instead of printing a fragile percentage.
That is the conversation the stewardship committee actually needs: the house figure for general wards, a separate ICU figure, and an honest flag where the numbers are too small. The numbers above are illustrative arithmetic, not data from a customer.
Who buys this
The buyer is a stewardship pharmacist, infectious diseases physician or microbiology supervisor at a hospital with ICUs who is asked whether empiric antipseudomonal choices still hold and currently answers from a once-a-year spreadsheet. If your unit cuts are the main need, see ICU antibiogram software. For carbapenem-resistant Pseudomonas counts that need quarterly watching, see carbapenem-resistant organisms reporting, and for the version handling behind the numbers see CLSI and EUCAST breakpoints. The current breakpoint tables are published in CLSI M100, and the CDC lists multidrug-resistant P. aeruginosa as a serious threat in its antimicrobial resistance threats report. Plans and prices are on the pricing page.
What it does not do
Antimicrobe does not flag individual patients, recommend a dose or replace the susceptibility result on a patient's own culture. It does not build combination antibiograms. It reports what the laboratory has resulted, as cumulative tables and trends, so keep your clinical surveillance system for patient-level alerts.
Related reading: ICU antibiogram software, hospital antibiogram software, ESBL antibiogram software, infection control surveillance software compared. The four steps from susceptibility testing data to an antibiogram cover the method end to end.
Questions
On this page's topic
What is a Pseudomonas antibiogram?
It is a cumulative susceptibility report for Pseudomonas aeruginosa that shows the percentage of first isolates per patient susceptible to each antipseudomonal drug, with isolate counts, usually by year and often by unit and specimen source. It guides empiric therapy before a patient's own culture result is back.
Can Antimicrobe report Pseudomonas susceptibility by ICU?
Yes. Unit and specimen source filters run on the same dataset, so the ICU and respiratory cuts come from one upload. Cells under 30 isolates are flagged and show the raw count, and you can pool two years to reach the threshold. Unit cuts are part of the Stewardship plan.
Does it handle the CLSI breakpoint changes for Pseudomonas?
Yes. Each table records the breakpoint version used, and a year of MIC data can be re-run under the current CLSI or EUCAST version, so a fall in piperacillin-tazobactam or tobramycin susceptibility can be checked against the rule change.
Does it need an interface to our laboratory system?
No. Your lab exports a susceptibility line list as CSV, you upload it and map the columns once. Most hospitals produce the first report on the day they start.
More on antimicrobial resistance reporting
- CLSI breakpoints A breakpoint revision can move a susceptibility rate by several points without one organism...
- WHONET WHONET is good software, it is free, and it is the global default for a reason. Most US team...
- TheraDoc competitors Most teams shopping for a TheraDoc alternative are not unhappy with the alerts. They are at...
- Sentri7 alternatives Sentri7 took two segments in the 2026 Best in KLAS report, so most teams looking for an alte...
- MedMined alternatives MedMined is now BD HealthSight Infection Advisor, sold next to BD HealthSight Clinical Advis...
- VigiLanz alternatives VigiLanz is sold by Inovalon in three hospital tiers now, and the antibiogram sits in the to...
Start with your own export
See your own resistance picture, cut the way you actually work
Build the antibiogram on the synthetic sample dataset, or drop in your own CSV and watch it parse without leaving your browser. When you want an account, one email address is the whole sign-up.
Your file is parsed in your browser and never uploaded. No card required.